Integrated laser platform receives CE Mark approval

Article

The Optimis Fusion integrated laser platform from Quantel Medical has received CE Mark approval. The system is a combination of advanced selective laser trabeculoplasty photoregeneration therapy with traditional YAG photodisruption treatment for treating both cataract and glaucoma.

The Optimis Fusion integrated laser platform from Quantel Medical has received CE Mark approval. The system is a combination of advanced selective laser trabeculoplasty photoregeneration therapy with traditional YAG photodisruption treatment for treating both cataract and glaucoma.

The integrated laser platform system's unique selective laser trabeculoplasty mode incorporates the most advanced laser technology available to target melanin-rich cells, which absorb the laser energy and induce a healing response that improves the function of the trabecular meshwork. Laser energy is delivered in short, fixed pulses over a large homogeneous spot size, which results in no thermal damage. With this gentle delivery, no permanent destruction to the trabecular meshwork occurs, and the structures are left intact. Selective laser trabeculoplasty can then be repeated if necessary.

The system's YAG mode delivers high-performance photodisruption for capsulotomy and peripheral iridotomy. A Gaussian laser beam profile allows for precise laser delivery using minimum energy levels, to avoid side effects such as lens pitting. An advanced two-point aiming beam allows for precise tissue targeting, to achieve fast and accurate targeting of the capsule. An adjustable anterior and posterior offset feature allows for easy focus adjustment in front of, behind, or at the point of disruption.

"We are proud to introduce an engineering breakthrough, which enables infrared and visible green nanosecond pulses to be produced by a single dual-mode cavity, reducing complexity and resulting in a more elegant and up-to-date combo laser design," said Jean-Marc Gendre, CEO of Quantel Medical.

Quantel has announced that it will immediately begin commercialization of the system in al CE Mark-approved countries and FDA approval is expected in 2014.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.